Company Description

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.

It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain.

The company was incorporated in 2022 and is based in New York, New York.

Metsera, Inc.

Country	United States
Founded	2022
IPO Date	Jan 31, 2025
Industry	Biotechnology
Sector	Healthcare
CEO	Christopher Bernard

Contact Details

Address: 3 World Trade Center, 175 Greenwich Street New York, New York 10007 United States
Phone	212 784 6595
Website	metsera.com

Stock Details

Ticker Symbol	MTSR
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$18.00
CIK Code	0002040807
ISIN Number	US59267L1070
SIC Code	2834

Key Executives

Name	Position
Clive A. Meanwell, M.B., Ch.B., M.D.	Executive Chairman of the Board of Directors
Christopher Whitten Bernard	President, Chief Executive Officer and Director
Christopher J. Visioli	Chief Financial Officer and Chief Business Officer
Steven Marso, M.D.	Chief Medical Officer
Brian Hubbard, Ph.D.	Chief Scientific Officer
Paul L. Berns	Director
Kristina M. Burow	Director
Joshua Pinto, Ph.D.	Director

Latest SEC Filings

Date	Type	Title
Mar 26, 2025	8-K	Current Report
Mar 26, 2025	10-K	Annual Report
Mar 10, 2025	8-K	Current Report
Feb 10, 2025	SCHEDULE 13D	Filing
Feb 5, 2025	SCHEDULE 13G	Filing
Feb 4, 2025	S-8	Securities to be offered to employees in employee benefit plans
Feb 3, 2025	8-K	Current Report
Jan 31, 2025	424B4	Prospectus
Jan 30, 2025	EFFECT	Notice of Effectiveness
Jan 29, 2025	CERT	Certification by an exchange approving securities for listing

View All SEC Filings